• Users Online: 161
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2017  |  Volume : 1  |  Issue : 2  |  Page : 84-87

Valbenazine: Drug review


Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Mahanjit Konwar
Department of Clinical Pharmacology, Multispeciality Building, Seth GS Medical College and KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aip.aip_41_17

Rights and Permissions

Valbenazine is the first drug approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia(TD) on April 11, 2017. It acts as a reversible inhibitor of vesicular monoamine transporter 2. It is available orally with a starting dose of 40mg once daily which can be increased after 1week to the recommended dose of 80mg. Clinical trials showed positive outcomes in Abnormal Involuntary Movement Scale and Clinical Global Impression-Global Improvement of TD score with respect to placebo. Valbenazine has an acceptable safety and tolerability profile, the most common side effect observed is somnolence. However, long-term study is lacking, and more data are required to establish its full benefits and concomitant risks which can be missed in the recent trials.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed734    
    Printed39    
    Emailed1    
    PDF Downloaded95    
    Comments [Add]    

Recommend this journal